CAMP4 Therapeutics Corp(CAMP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.23 | Insider Own | 50.81% | Shs Outstand | 51.9M | Perf Week | 15.04% |
| Market Cap | 0.24B | Forward P/E | - | EPS next Y | 31.25% | Insider Trans | -1.69% | Shs Float | 30.9M | Perf Month | -3.47% |
| Enterprise Value | 0.16B | PEG | - | EPS next Q | -0.19 | Inst Own | 53.3% | Short Float | 11.18% | Perf Quarter | 13.04% |
| Income | -0.11B | P/S | 57.99 | EPS this Y | 56.27% | Inst Trans | 1.11% | Short Ratio | 13.28 | Perf Half Y | -6.47% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 34.39% | ROA | -148.23% | Short Interest | 3.45M | Perf YTD | -36.38% |
| Book/sh | -0.01 | P/C | 2.81 | EPS past 3/5Y | -5.31% - | ROE | -545.85% | 52W High | -49.68% ($7.75) | Perf Year | 1.04% |
| Cash/sh | 1.39 | P/FCF | - | Sales past 3/5Y | - | ROIC | -12228.51% | 52W Low | 34.48% ($2.90) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.4% | Gross Margin | 57.12% | Volatility(W/M) | 7.88% 8.35% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 37.91 | Sales Y/Y TTM | 40.21% | Oper. Margin | -1242.5% | ATR (14) | 0.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.7 | EPS Q/Q | 7.3% | Profit Margin | -2543.74% | RSI (14) | 57.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.7 | Sales Q/Q | 18.84% | SMA20 | 9.69% ($3.56) | Beta | 0.27 | Target Price | $9.9 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -0.05% ($3.9) | Rel Volume | 0.58 | Prev Close | $3.65 |
| Employees | 48 | LT Debt/Eq | - | EPS/Sales Surpr. | -174.36% 9.81% | SMA200 | -7.8% ($4.23) | Avg Volume(3M) | 0.26M | Price | $3.9 |
| IPO | 2024/10/11 | Option/Short | No/Yes | Trades | 1134 | Volume | 151,983 | Change | 6.85% |
🧬 Camp4 Therapeutics trades under the ticker CAMP and is a U.S. clinical-stage biotech that aims to treat genetic diseases by targeting regulatory RNA to boost gene expression. Rather than directly injecting proteins, its approach prompts the body to produce more of the deficient proteins on its own, building a pipeline targeting rare genetic disorders such as urea cycle disorders and SYNGAP1-related conditions.
Over the past 1 year, on the lower side
50% below its 1-year high.
Traded less than usual. That is 58% of its average volume.
CAMP has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +56.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $5,799. Peers typically go for $1,089.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 53.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #288 of 594 in the industry
Based on market cap of $245M.
EVMN#285 Evommune Inc $247M PER - 
ELDN#286 Eledon Pharmaceuticals Inc $247M PER - 
VNDA#287 Vanda Pharmaceuticals Inc $245M PER - CAMP#288 CAMP4 Therapeutics Corp $245M PER - 
ACIU#289 AC Immune SA $241M PER - 
FAQ
What kind of company is CAMP?
CAMP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CAMP?
The market cap of CAMP is approximately $245M, ranking 3,860 within its sector.
What is the 52-week high and low for CAMP?
CAMP has recorded a 52-week high of $7.75 and a low of $2.90.
